Ann: Cann and Emyria mutually end collaboration, page-19

Cann Group CEO Peter Crock said:
“Satipharm CBD products are currently sold over-the-counter at major pharmacies and health food retailers in the UK and Cann is in discussions with major healthcare companies in relation to global distribution rights to the product.”
“Our international expansion plans for the Satipharm CBD products prioritise Australia as a key market, where consumer interest and demand for CBD-only products continues to grow.”“The TGA assessment and approval process is rigorous and provides Australian consumers with a high degree of confidence around quality and safety.”
“Our recent institutional placement secured the funding necessary for Cann to independently pursue our registration plans and to seek to be first to market in Australia with a TGA approved product.”